Literature DB >> 35881260

Anti-staphylococcal responses and their relationship with HLA-DR-DQ polymorphism in granulomatosis with polyangiitis: a preliminary evidence of association with disease outcome.

Lekha Rani1, Jagdeep Singh1, Aman Sharma2, Heera Singh1, Indu Verma3, Naresh K Panda4, Ranjana W Minz5.   

Abstract

Chronic nasal carriage of Staphylococcus aureus (S. aureus) is a risk factor for relapse of granulomatosis with polyangiitis (GPA), and genetic susceptibility to infections and autoimmune diseases is majorly affected by HLA genes. Previous studies have shown the association of HLA Class-II genes with GPA susceptibility. Here, we aim to assess immune responses of GPA patients against S. aureus antigens in relation to the HLA-DR-DQ genes polymorphism to determine the disease outcome. A total of 45 GPA patients and 128 healthy controls during 2010-2012 were included in this case-control study. HLA-DRB1/DQB1 allele typing was performed by polymerase chain reaction-sequence-specific primer (PCR-SSP) method. Immune responses against S. aureus antigens were investigated in 20 active vs. remitting GPA (after 6 months of cyclophosphamide and glucocorticoids) patients by Western blot. Statistical analysis was performed using χ2 test and Fisher's exact test. We observed a significant association of DRB1*08, DRB1*16 and DQB1*04 alleles with GPA susceptibility, whereas DRB1*15, DRB1*10 and DQB1*05 alleles were suggested as protective alleles. Among S. aureus antigens, active GPA patients' sera reacted more strongly with 34 and 24 kDa antigens of S. aureus than remitting and healthy control  sera. Furthermore, we observed that the lack of DQB1*06 allele confers complete remission even in the presence of anti-S. aureus antibodies against 24 kDa protein. Our findings suggest that the presence of DQB1*06 allele and S. aureus infection may prolong active disease. Further, our study indicates the potential of using anti-staphylococcal medications for achieving remission in patients having HLA-DQB1*06 allele.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Clinical outcome; GPA; HLA; Immune response; S. aureus

Year:  2022        PMID: 35881260     DOI: 10.1007/s10238-022-00865-6

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   5.057


  44 in total

1.  Levels of antibody against 11 Staphylococcus aureus antigens in a healthy population.

Authors:  Patricia Colque-Navarro; Gunnar Jacobsson; Rune Andersson; Jan-Ingmar Flock; Roland Möllby
Journal:  Clin Vaccine Immunol       Date:  2010-05-05

Review 2.  Diagnosis and classification of granulomatosis with polyangiitis (aka Wegener's granulomatosis).

Authors:  Pamela M K Lutalo; David P D'Cruz
Journal:  J Autoimmun       Date:  2014-01-29       Impact factor: 7.094

3.  Severity of Staphylococcus aureus infection of the skin is associated with inducibility of human beta-defensin 3 but not human beta-defensin 2.

Authors:  Philipp Zanger; Johannes Holzer; Regina Schleucher; Helmut Scherbaum; Birgit Schittek; Sabine Gabrysch
Journal:  Infect Immun       Date:  2010-04-19       Impact factor: 3.441

Review 4.  Possible Role of Staphylococcal Enterotoxin B in the Pathogenesis of Autoimmune Diseases.

Authors:  Jing Li; Jie Yang; Yu-wei Lu; Song Wu; Ming-rui Wang; Ji-min Zhu
Journal:  Viral Immunol       Date:  2015-06-18       Impact factor: 2.257

5.  Nasal carriage of Staphylococcus aureus and endonasal activity in Wegener s granulomatosis as compared to rheumatoid arthritis and chronic Rhinosinusitis with nasal polyps.

Authors:  Martin Laudien; Stefan D Gadola; Rainer Podschun; Jürgen Hedderich; Jens Paulsen; Eva Reinhold-Keller; Elena Csernok; Petra Ambrosch; Bernhard Hellmich; Frank Moosig; Wolfgang L Gross; Hany Sahly; Peter Lamprecht
Journal:  Clin Exp Rheumatol       Date:  2010 Jan-Feb       Impact factor: 4.473

Review 6.  Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.

Authors:  Steven Y C Tong; Joshua S Davis; Emily Eichenberger; Thomas L Holland; Vance G Fowler
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

7.  Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis.

Authors:  C A Stegeman; J W Tervaert; W J Sluiter; W L Manson; P E de Jong; C G Kallenberg
Journal:  Ann Intern Med       Date:  1994-01-01       Impact factor: 25.391

Review 8.  ANCA-associated vasculitis.

Authors:  A Richard Kitching; Hans-Joachim Anders; Neil Basu; Elisabeth Brouwer; Jennifer Gordon; David R Jayne; Joyce Kullman; Paul A Lyons; Peter A Merkel; Caroline O S Savage; Ulrich Specks; Renate Kain
Journal:  Nat Rev Dis Primers       Date:  2020-08-27       Impact factor: 52.329

9.  Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group.

Authors:  C A Stegeman; J W Tervaert; P E de Jong; C G Kallenberg
Journal:  N Engl J Med       Date:  1996-07-04       Impact factor: 91.245

10.  Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement.

Authors:  K Zycinska; K A Wardyn; T M Zielonka; R Krupa; W Lukas
Journal:  Eur J Med Res       Date:  2009-12-07       Impact factor: 2.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.